

CONTENTS

1	INTRODUCTION	1-40
1.1	Global cancer statistics	1-2
1.2	Chemotherapy and its limitations	2-3
1.3	Role of tyrosine kinases in cancer	3-4
1.3.1	Epidermal growth factor receptors (EGFRs)	4
1.3.2	Vascular endothelial growth factor receptors (VEGFRs)	4-5
1.3.3	Platelet-derived growth factor receptors (PDGFRs)	5-6
1.3.4	Insulin-like growth factor I receptor (IGF-IR)	6
1.3.5	Fibroblast growth factor receptors (FGFRs)	6-7
1.3.6	Hepatocyte growth factor receptor (HGFR)	7-8
1.4	Endothelial Growth Factor Receptors (EGFRs) and related issues	8
1.4.1	Introduction	8
1.4.2	Structure and types of EGFRs	9
1.4.2.1	Primary and domain structures of the EGFRs	10
1.4.2.2	ErbB2	10-11
1.4.2.3	ErbB3 and ErbB4	11
1.4.3	Extracellular ligands of ErbB receptors	11-12
1.4.4	Activation of the EGFR	12-14
1.4.5	Signaling pathways of tyrosine kinase receptors	14-16
1.4.6	Receptor internalization and trafficking	16-17
1.4.7	Defective EGFR1 activity can be caused due to many reasons	17
1.4.8	Approaches to inhibit EGFR overexpression	18
1.4.9	Present status of EGFR inhibitors in cancer	18
1.4.9.1	Monoclonal antibodies	18-19

1.4.9.2	Small molecule inhibitors of EGFRs	19-21
1.5	Literature review of quinazoline EGFR inhibitors	22-40
2	AIMS AND OBJECTIVES	41-44
3	RESULTS AND DISCUSSIONS	45-82
3.1	Chemical work	45-80
A	Synthesis of starting materials and intermediates	45-49
A.1	Synthesis of biphenylacetic acid (4)	45-46
A.2	Synthesis of 2-naphthylacetic acid (8)	46
A.3	Synthesis of 6-methoxy-2-naphthylacetic acid (8a)	46
A.4	Synthesis of methyl 4-hydroxy-3-methoxybenzoate (13)	47
A.5	Synthesis of methyl 4-hydroxy-3-methoxy-2-nitrobenzoate (15)	47-48
A.6	Synthesis of 4-arylmethoxy-3-chloroaniline (21, 22)	48
A.7	Synthesis of 3-chloro-4-(2-pyridinyl)methoxyaniline (28)	48-49
B	Synthesis of 2-amino-4-chloroalkoxy-5-methoxybenzamides (40, 41)	49-50
C	Synthesis of 7-(3-substituted aminopropoxy) derivatives of quinazolinones (54a-59g)	50-63
D	Synthesis of 7-(2-substitutedaminoethoxy) derivatives of quinazolinones (68a-71g)	63-70
E	Synthesis of 4-anilinoquinazoline derivatives (83a-88c)	70-80
3.2	Biological work	80-81
4	EXPERIMENTAL	82-139
5	REFERENCES	140-52